As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several
chemotherapeutics used in the treatment of all the most common malignancies. There are …

Advances in supportive care have increased the likelihood that previously less common
adverse effects of chemotherapy will be more evident. The incidence of chemotherapy …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy
that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by …

Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer
treatment and its incidence is growing. It significantly affects quality of life and is a dose …

Peripheral neuropathy is a common dose-limiting toxicity of chemotherapy. Chemotherapy-
induced peripheral neuropathy (CIPN) causes numerous debilitating symptoms, impairs …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …